OncoVanta Therapeutics
PrivateCompany Overview
OncoVanta Therapeutics is a biotechnology company that develops TCR-T Cell therapies targeting mutant TP53-driven solid tumors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Government Contracts
AI Layer
Non-AI
Keywords
TCR-T therapymutant TP53solid tumorsengineered T-cellscell therapycancer immunotherapyT-cell receptor therapypancreatic cancerintracellular protein targetingpreclinical biotechnologyoncology
Historical Pricing
Historical view of private secondary pricing and transaction trends.
OncoVanta Therapeutics Comparables
Compare OncoVanta Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Anocca | 83% | |
| Affini-T Therapeutics | 82% | |
| 3T Biosciences | 79% | |
OncoVanta Therapeutics Funding Rounds
Historical fundraising activity
OncoVanta Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about OncoVanta Therapeutics's valuation, stock price, and market status.